Regeneron Pharmaceuticals Inc.

09/08/2022 | Press release | Distributed by Public on 09/08/2022 07:03

Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals